Stock Scorer

Guided Therapeutics Inc (GTHP)

Guided Therapeutics Inc reported revenue of 0 USD for the quarter ending 30 June 2026, down 100.0% from 117K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 0 -100.0%
Gross Profit Q2 '26 · ending 30 June 2026 0 -100.0%
Operating Income Q2 '26 · ending 30 June 2026 -478K —
Net Income Q2 '26 · ending 30 June 2026 -605K —
Cost of Revenue Q2 '26 · ending 30 June 2026 0 -100.0%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -319K —
Free Cash Flow Q4 '25 · ending 31 December 2025 -291K —
Shares Outstanding Q2 '26 · ending 30 June 2026 96.5M +41.4%
EPS Q2 '26 · ending 30 June 2026 -0.04 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 767K-2.4M-3.2M-1.1M
20242024-12-31 7K-2.1M-2.4M-1.1M
20232023-12-31 98K-3.5M-3.5M-1.7M
20222022-12-31 13K-3.3M-4.3M-1.5M
20212021-12-31 81K-2.4M-2.1M-1.6M
20202020-12-31 102K-1.1M-279K-1.9M
20192019-12-31 36K-937K-1.9M-806K
20182018-12-31 57K-1.5M1M—
20172017-12-31 244K-3.1M-10.7M—
20162016-12-31 0-3.8M-4M-1.8M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-300
Q1 '262026-03-310
Q4 '252025-12-31590K
Q3 '252025-09-3060K
Q2 '252025-06-30117K
Q1 '252025-03-310
Q4 '242024-12-311K
Q3 '242024-09-300
Q2 '242024-06-300
Q1 '242024-03-316K
Q4 '232023-12-3132K
Q3 '232023-09-300
Q2 '232023-06-3044K
Q1 '232023-03-3122K
Q4 '222022-12-310
Q3 '222022-09-303K
Q2 '222022-06-305K
Q1 '222022-03-315K
Q4 '212021-12-3160K
Q3 '212021-09-3019K

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '262026-06-300
Q1 '262026-03-310
Q4 '252025-12-31458K
Q3 '252025-09-3035K
Q2 '252025-06-3079K
Q1 '252025-03-310
Q4 '242024-12-31-2K
Q3 '242024-09-300
Q2 '242024-06-300
Q1 '242024-03-314K
Q4 '232023-12-3116K
Q3 '232023-09-30-4K
Q2 '232023-06-3011K
Q1 '232023-03-3113K
Q4 '222022-12-31-79K
Q3 '222022-09-303K
Q2 '222022-06-304K
Q1 '222022-03-314K
Q4 '212021-12-3141K
Q3 '212021-09-30-23K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-478K
Q1 '262026-03-31-302K
Q4 '252025-12-31-710K
Q3 '252025-09-30-485K
Q2 '252025-06-30-763K
Q1 '252025-03-31-414K
Q4 '242024-12-31-534K
Q3 '242024-09-30-561K
Q2 '242024-06-30-655K
Q1 '242024-03-31-359K
Q4 '232023-12-31-485K
Q3 '232023-09-30-623K
Q2 '232023-06-30-1.5M
Q1 '232023-03-31-843K
Q4 '222022-12-31-948K
Q3 '222022-09-30-1.2M
Q2 '222022-06-30-717K
Q1 '222022-03-31-443K
Q4 '212021-12-31-435K
Q3 '212021-09-30-487K

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-605K
Q1 '262026-03-31-500K
Q4 '252025-12-31-1.2M
Q3 '252025-09-30-742K
Q2 '252025-06-30-811K
Q1 '252025-03-31-427K
Q4 '242024-12-31-652K
Q3 '242024-09-30-654K
Q2 '242024-06-30-709K
Q1 '242024-03-31-402
Q4 '232023-12-31-386K
Q3 '232023-09-30-677K
Q2 '232023-06-30-1.6M
Q1 '232023-03-31-869K
Q4 '222022-12-31-1.8M
Q3 '222022-09-30-1.1M
Q2 '222022-06-30-926K
Q1 '222022-03-31-507K
Q4 '212021-12-31-444K
Q3 '212021-09-3068K

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-300
Q1 '262026-03-310
Q4 '252025-12-31132K
Q3 '252025-09-3025K
Q2 '252025-06-3038K
Q1 '252025-03-310
Q4 '242024-12-313K
Q3 '242024-09-300
Q2 '242024-06-300
Q1 '242024-03-312K
Q4 '232023-12-3116K
Q3 '232023-09-304K
Q2 '232023-06-3033K
Q1 '232023-03-319K
Q4 '222022-12-3179K
Q3 '222022-09-300
Q2 '222022-06-301K
Q1 '222022-03-311K
Q4 '212021-12-3119K
Q3 '212021-09-3042K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-319K
Q1 '262026-03-31-617K
Q4 '252025-12-31-291K
Q3 '252025-09-30-277K
Q2 '252025-06-30-169K
Q1 '252025-03-31-331K
Q4 '242024-12-31-332K
Q3 '242024-09-30-473K
Q2 '242024-06-30-214K
Q1 '242024-03-31-100K
Q4 '232023-12-31-336K
Q3 '232023-09-30-473K
Q2 '232023-06-30-438K
Q1 '232023-03-31-499K
Q4 '222022-12-31-339K
Q3 '222022-09-30-612K
Q2 '222022-06-30-349K
Q1 '222022-03-31-179K
Q4 '212021-12-31159K
Q3 '212021-09-30-739K

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '252025-12-31-291K
Q4 '242024-12-31-332K
Q4 '232023-12-31-336K
Q3 '232023-09-30-473K
Q2 '232023-06-30-438K
Q1 '232023-03-31-499K
Q4 '222022-12-31-342K
Q3 '222022-09-30-615K
Q2 '222022-06-30-366K
Q1 '222022-03-31-193K
Q4 '212021-12-31155K
Q3 '212021-09-30-744K
Q2 '212021-06-30-696K
Q1 '212021-03-31-321K
Q4 '202020-12-31-331K
Q3 '202020-09-30-606K
Q2 '202020-06-30-409K
Q1 '202020-03-31-530K
Q4 '192019-12-31-204K
Q3 '192019-09-30-228K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3096.5M
Q1 '262026-03-3188.8M
Q3 '252025-09-3081.7M
Q2 '252025-06-3078.8M
Q1 '252025-03-3168.3M
Q3 '242024-09-3057M
Q2 '242024-06-3056M
Q1 '242024-03-3154.8M
Q3 '232023-09-3051.5M
Q2 '232023-06-3051M
Q1 '232023-03-3149.3K
Q3 '222022-09-3034.8M
Q2 '222022-06-3026.3M
Q1 '222022-03-3120.7M
Q3 '212021-09-3013.4M
Q2 '212021-06-3013.3M
Q1 '212021-03-3113.2M
Q3 '202020-09-3060.3K
Q2 '202020-06-3011.9K
Q1 '202020-03-3165.6K

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.04
Q1 '262026-03-31-0.04
Q4 '252025-12-31-0.04
Q3 '252025-09-30-0.05
Q2 '252025-06-30-0.05
Q1 '252025-03-31-0.05
Q4 '222022-12-31-0.16
Q3 '222022-09-30-0.16
Q2 '222022-06-30-0.13
Q1 '222022-03-31-0.18
Q4 '212021-12-31-0.17